Skip to main content

Nature Communications Archives

Study suggests new mechanism for lipid transporter

Sep. 15, 2022—A new model suggests that a protein involved in the generation of high-density lipoprotein (HDL) works differently than previously thought.

Read more


Inflammatory driver of obesity

Aug. 25, 2022—Blocking the EGF receptor signaling pathway in immune system macrophages represents a new target for improving insulin resistance in people with obesity.

Read more


Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine

Jul. 20, 2022—In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.

Read more


Study advances understanding of bacterial bioterrorism agent

Apr. 7, 2022—Vanderbilt researchers have identified a critical regulatory factor in the bacterium that causes the disease anthrax and has been used as a biological weapon.

Read more


New method enhances efforts to identify drug repurposing targets

Jan. 20, 2022—Researchers at Vanderbilt University Medical Center have developed a new method for identifying drugs for the repurposing trials that can lead to new indications for drugs already in use.

Read more


‘Multi-omics’ reveals treatment option for breast cancer subtype

Nov. 18, 2021—  by Bill Snyder In a multidisciplinary collaboration, researchers at Vanderbilt University Medical Center and the University of Miami Miller School of Medicine have identified a subtype of triple-negative breast cancer (TNBC) that appears to be able to escape detection by the immune system and evade immunotherapy. Their report, published Nov. 1 in the journal...

Read more


Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription

Sep. 30, 2021—Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.

Read more


Discovery offers insight for development of cancer therapies targeting mutant p53

Sep. 2, 2021—Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.

Read more


Study identifies monoclonal antibodies that may neutralize many norovirus variants

Jul. 16, 2021—Researchers at Vanderbilt University Medical Center (VUMC) and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.

Read more


Personalized Structural Biology aids cancer treatment decisions

Apr. 8, 2021—Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

Read more


New predictors of prostate cancer risk

Sep. 17, 2020—An international group of researchers including Vanderbilt epidemiologists has identified new DNA methylation biomarkers associated with prostate cancer risk.

Read more


‘Scavenger’ molecule may point to new atherosclerosis treatment

Aug. 20, 2020—A small-molecule “scavenger” that reduces inflammation and formation of atherosclerotic plaque in blood vessels in mice potentially could lead to a new approach for treating atherosclerosis in humans, according to researchers at Vanderbilt University Medical Center.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more